Xolremdi

mavorixafor

Approval

ApplicationNDA 218709
Approval dateApr 26, 2024
Approval year2024
SponsorX4 Pharms

FDA-approved use

To treat WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis)

Approval package

Query with Claude

The fda-analyst skill answers natural-language questions about this approval by fetching the relevant FDA review PDFs at query time.

git clone https://github.com/cbetz/trove
cp -r trove/skills/fda-analyst ~/.claude/skills/

Example prompts for Xolremdi: